A comparison between warfarin and apixaban: A patient's perspective

BACKGROUND: Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a t...

Full description

Bibliographic Details
Main Authors: Abdullah U Althemery, Abdullah A Alfaifi, Abdulrahman Alturaiki, Maha A. L. Ammari, Khizra Sultana, Leanne Lai
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Annals of Thoracic Medicine
Subjects:
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=2;spage=84;epage=89;aulast=Althemery
id doaj-d8d282c68e044e52bbf557df6a0052c7
record_format Article
spelling doaj-d8d282c68e044e52bbf557df6a0052c72020-11-25T02:27:38ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572020-01-01152848910.4103/atm.ATM_352_19A comparison between warfarin and apixaban: A patient's perspectiveAbdullah U AlthemeryAbdullah A AlfaifiAbdulrahman AlturaikiMaha A. L. AmmariKhizra SultanaLeanne LaiBACKGROUND: Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a treatment route. AIMS: This study compared the patients' perspectives on treatment with warfarin versus apixaban using the QOL measures. SETTINGS AND DESIGN: This cross-sectional study was conducted in 2019 for patients treated with either warfarin or apixaban at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia. METHODS: We used a series of descriptive statistics to examine the differences in sociodemographic characteristics among patients. A propensity score-matching approach was employed to reduce the effect of confounding variables that often influence treatment selection. Greedy matching approach was used to analyze the QOL. RESULTS: A total of 388 patients were identified, of which 124 were matched between the two groups (62 patients in each group). Most of the patients were female, married, below the sufficiency level, educated, and nonsmokers. The patients using warfarin had a significantly better health state (M = 69.64, standard deviation [SD] = 16.52) than those using apixaban (M = 66.33, SD = 23.17), P = 0.011. CONCLUSIONS: Future studies should explore why patients using apixaban showed lower QOL scores and improve health-care providers' awareness of these issues.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=2;spage=84;epage=89;aulast=Althemeryapixabaneuroqoloral anticoagulantspatient-reported outcomespropensity score matchingwarfarin
collection DOAJ
language English
format Article
sources DOAJ
author Abdullah U Althemery
Abdullah A Alfaifi
Abdulrahman Alturaiki
Maha A. L. Ammari
Khizra Sultana
Leanne Lai
spellingShingle Abdullah U Althemery
Abdullah A Alfaifi
Abdulrahman Alturaiki
Maha A. L. Ammari
Khizra Sultana
Leanne Lai
A comparison between warfarin and apixaban: A patient's perspective
Annals of Thoracic Medicine
apixaban
euroqol
oral anticoagulants
patient-reported outcomes
propensity score matching
warfarin
author_facet Abdullah U Althemery
Abdullah A Alfaifi
Abdulrahman Alturaiki
Maha A. L. Ammari
Khizra Sultana
Leanne Lai
author_sort Abdullah U Althemery
title A comparison between warfarin and apixaban: A patient's perspective
title_short A comparison between warfarin and apixaban: A patient's perspective
title_full A comparison between warfarin and apixaban: A patient's perspective
title_fullStr A comparison between warfarin and apixaban: A patient's perspective
title_full_unstemmed A comparison between warfarin and apixaban: A patient's perspective
title_sort comparison between warfarin and apixaban: a patient's perspective
publisher Wolters Kluwer Medknow Publications
series Annals of Thoracic Medicine
issn 1817-1737
1998-3557
publishDate 2020-01-01
description BACKGROUND: Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a treatment route. AIMS: This study compared the patients' perspectives on treatment with warfarin versus apixaban using the QOL measures. SETTINGS AND DESIGN: This cross-sectional study was conducted in 2019 for patients treated with either warfarin or apixaban at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia. METHODS: We used a series of descriptive statistics to examine the differences in sociodemographic characteristics among patients. A propensity score-matching approach was employed to reduce the effect of confounding variables that often influence treatment selection. Greedy matching approach was used to analyze the QOL. RESULTS: A total of 388 patients were identified, of which 124 were matched between the two groups (62 patients in each group). Most of the patients were female, married, below the sufficiency level, educated, and nonsmokers. The patients using warfarin had a significantly better health state (M = 69.64, standard deviation [SD] = 16.52) than those using apixaban (M = 66.33, SD = 23.17), P = 0.011. CONCLUSIONS: Future studies should explore why patients using apixaban showed lower QOL scores and improve health-care providers' awareness of these issues.
topic apixaban
euroqol
oral anticoagulants
patient-reported outcomes
propensity score matching
warfarin
url http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=2;spage=84;epage=89;aulast=Althemery
work_keys_str_mv AT abdullahualthemery acomparisonbetweenwarfarinandapixabanapatientsperspective
AT abdullahaalfaifi acomparisonbetweenwarfarinandapixabanapatientsperspective
AT abdulrahmanalturaiki acomparisonbetweenwarfarinandapixabanapatientsperspective
AT mahaalammari acomparisonbetweenwarfarinandapixabanapatientsperspective
AT khizrasultana acomparisonbetweenwarfarinandapixabanapatientsperspective
AT leannelai acomparisonbetweenwarfarinandapixabanapatientsperspective
AT abdullahualthemery comparisonbetweenwarfarinandapixabanapatientsperspective
AT abdullahaalfaifi comparisonbetweenwarfarinandapixabanapatientsperspective
AT abdulrahmanalturaiki comparisonbetweenwarfarinandapixabanapatientsperspective
AT mahaalammari comparisonbetweenwarfarinandapixabanapatientsperspective
AT khizrasultana comparisonbetweenwarfarinandapixabanapatientsperspective
AT leannelai comparisonbetweenwarfarinandapixabanapatientsperspective
_version_ 1724841888844873728